Web30 de jul. de 2024 · Recently, belzutifan (PT2977/MK-6482; Fig. 5) underwent phase II clinical trials as a HIF-2α inhibitor for patients with VHL disease-associated renal cell carcinoma (NCT03401788). Web13 de ago. de 2024 · WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. The WELIREG label contains a boxed warning that exposure to WELIREG during pregnancy can cause …
3-[(1 S,2 S,3 R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan
Web656MO - Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC) Date 18 Sep 2024 Session Mini oral session - Genitourinary tumours, non-prostate Topics Tumour Site Renal Cell Cancer Presenters David McDermott Citation Web22 de dez. de 2003 · Biallelic inactivation of the von Hippel–Lindau tumor suppressor gene (VHL) is linked to the development of hereditary (VHL-associated) and sporadic clear … north carolina congressional race polls
Revisiting the HIF switch in the tumor and its ... - Trends in Cancer
WebHypoxia is a hallmark of all solid tumors and their metastases. This leads to activation of the hypoxia-inducible factor (HIF) family of transcription factors, which modulate gene expression within both tumor cells and immune cells within the tumor microenvironment, influencing tumor progression and treatment response. The best characterized HIF … Web19 de dez. de 2024 · Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible factor-2α (HIF-2α). PT2385 is a first-in-class HIF-2α antagonist. Objectives of this first-in-human study were to characterize the safety, pharmacokinetics, … Web25 de mai. de 2024 · 5003 Background: Patients (pts) with Von Hippel-Lindau disease (VHL) are at risk for several cancers, including clear cell renal cell carcinoma (ccRCC). Inactivation of VHL results in constitutive activation of the HIF-2α transcription factor, which drives tumor growth. MK-6482, a potent, selective, small molecule HIF-2α inhibitor, has … north carolina congressional districts 2022